1612 K St NW Suite 1101, Washington, DC 20006
1612 K St NW Suite 1101, Washington, DC 20006
Hundreds of women who experienced complications from BioZorb breast tissue markers are pursuing claims against manufacturer Hologic. Bellwether cases are already moving under coordinated scheduling orders, with formal MDL consolidation expected. Cornerstone Law is reviewing cases nationwide — with no upfront cost to you.
Where the Cases Stand
No formal MDL has been created yet, but BioZorb litigation is already functioning like a coordinated mass tort — with unified scheduling orders, standardized discovery, and synchronized bellwether preparation across multiple federal districts.
Litigation accelerates sharply as evidence of widespread device failure becomes public, with hundreds of cases filed across state and federal courts.
A unified scheduling order sets deadlines for fact discovery, expert disclosures, and bellwether selection across early cases, including Taylor, Deuel, Kresch, and Gibson.
Multiple federal cases advance under coordinated scheduling while the JPML actively considers centralization into a numbered BioZorb MDL.
Once the JPML rules, expect a numbered MDL with coordinated discovery and a formal bellwether trial program that will help shape settlement values.
What Plaintiffs Allege
Plaintiffs allege the BioZorb marker was defectively designed and that Hologic failed to adequately warn surgeons and patients of known risks — with complications ranging across some of the more serious outcomes possible from a surgical implant.
Despite being marketed as fully absorbable, the device is alleged to have persisted in patients' bodies, causing ongoing inflammation, fibrosis, and chronic pain.
Reports describe the marker shifting position within the breast, complicating radiation delivery and causing additional injury.
In severe cases, the device extruded through the skin, requiring emergency surgical intervention and leaving permanent scarring.
Patients report permanent cosmetic deformity and nerve damage — injuries plaintiffs say they weren't warned about before surgery.
Device failure is alleged to have interfered with radiation therapy guidance, the device's core purpose, potentially compromising cancer treatment outcomes.
Plaintiffs allege Hologic knew of these risks and failed to disclose them to surgeons or patients before implantation.
Eligibility
You may qualify if you received a BioZorb implant following breast-conserving surgery (lumpectomy) and later experienced one or more of the following complications.
Common Questions
Deadlines can run from the date of your surgery or the date you discovered a complication, so it's worth having your specific situation reviewed even if things currently seem fine.
We handle BioZorb cases on contingency — no upfront fee, and we only get paid if we recover compensation for you.
Not formally — cases are currently coordinated through scheduling orders across federal districts while the JPML considers formal MDL consolidation. That could change as the litigation develops.
Having the device removed doesn't disqualify a claim — the complications and any additional surgery required are often central to the case.
We represent women who suffered complications from BioZorb implants. Find out whether your diagnosis and complications qualify for a claim.
Get a Free Case ReviewNo fee unless we recover compensation for you. Call 1-800-928-9445.